Combined with child–parent screening, it would be both cost-effective and sustainable.12 NICE assumed testing costs for cholesterol of £1.60 per sample and for FH mutation testing (sequencing the LDLR, APOB and PCSK9 genes) of £400 per sample.12 Applying these charges to integrated CPCS means the cost per case identified would be about £1560 and the cost per child screened about £6 – less than the cost of administering one influenza vaccination (£9.80).13 The costs of CPCS will decline as the cost of FH mutation testing declines. This evidence concerns the gene PCSK9 and influenza.